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1. Introduction 
Prostate cancer is the leading cancer diagnosis in men, and the second cuase, after lung 
cancer, of cancer death in men in the U.S. Worldwide is the fourth most common cancer in 
men with variable incidence and mortality rates, based on geographic regions (1). In Europe 
is the most common solid tumor, with an incidence of 214 cases per 1000 men, 
outnumbering the lung and colorectal cancers, and is the second most common cause of 
cancer death in men. 
In recent years, the incidence of prostate cancer is increasing in most countries due to the 
improvement and widespread use of PSA, aging and probably a real increase in incidence. 
In men after 40 years there is a progressively incidence increase, with a peak at age 80. The 
countries with the highest mortality rate for prostate cancer are: Switzerland, Scandinavia 
and the USA-adjusted death rates by age group between 15-20/100.000 inhabitants. By 
contrast, the Asian countries with Japan and China leading the way, have the lowest 
mortality rate (less than 5 per 100,000 population) (1). 
The geographic incidence variations of prostate Cancer are multiple and complex, but there 
are genetic and environmental factors, which seem to be more involved in its genesis. 
African Americans are those who have higher rates of prostate ca. As mentioned above, 
China and Japan have lower rates in the incidence of prostate ca and USA one of the highest 
in the world, well, it is noteworthy that Asian Americans have lower incidence rate of 
prostate cancer than white Americans, the indicating that the genetic factor is crucial in the 
development of the disease. 
The overall increase in the incidence of prostate cancer worldwide in recent decades, is 
justified with the development of PSA screening protocols of prostate Cancer. The diagnosis 
of prostate cancer is based on the determination of serum PSA. The risk of prostate cancer is 
depending on Serum PSA (2): 
 
PSA 0-2 ng / ml: 15-25%. 
PSA 2-4 ng / ml: 17-32% 
PSA 4-10 ng / ml: 17-32% 
PSA> 10 ng / ml: 43-65%. 
 
There is still much controversy among health professionals about what is the best protocol 
for the screening of prostate cancer. The long awaited results of two prospective, 
randomised trials were published in 2009. The Prostate, Lung, Colorectal, and Ovarian 
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(PLCO) Cancer Screening Trial randomly assigned 76,693 men at 10 US centres to receive 
either annual screening with PSA and DRE or standard care as the control. After 7 years’ 
follow-up, the incidence of prostate cancer per 10,000 person-years was 116 (2,820 cancers) 
in the screening group and 95 (2,322cancers) in the control group (rate ratio, 1.22) (3). The 
incidence of death per 10,000 person-years was 2.0 (50 deaths) in the screened group and 1.7 
(44 deaths) in the control group (rate ratio, 1.13). The data at 10 years were 67% complete 
and consistent with these overall findings. The PLCO project team concluded that prostate 
cancer related mortality was very low and not significantly different between the two study 
groups. The European Randomized Study of Screening for Prostate Cancer (ERSPC) 
included a total of 162,243 men from seven countries aged between 55 and 69 years. The 
men were randomly assigned to a group offered PSA screening at an average of once every 
4 years or to an unscreened control group. During a median follow-up of 9 years, the 
cumulative incidence of prostate cancer was 8.2% in the screened group and 4.8% in the 
control group (4). The rate ratio for death from prostate cancer was 0.80 in the screened 
group compared with the control group. The absolute risk difference was 0.71 deaths per 
1,000 men. This means that 1410 men would need to be screened and 48 additional cases of 
prostate cancer would need to be treated to prevent one death from prostate cancer. The 
ERSPC investigators concluded that PSA-based screening reduced the rate of death from 
prostate cancer by 20%, but was associated with a high risk of over-diagnosis.  
Both trials have received considerable attention and comments. In the PLCO trial, the rate 
of compliance in the screening arm was 85% for PSA testing and 86% for DRE. However, 
the rate of contamination in the control arm was as high as 40% in the first year and 
increased to 52% in the sixth year for PSA testing and ranged from 41% to 46% for DRE. 
Furthermore, biopsy compliance was only 40-52% versus 86% in the ERSPC. Thus, the 
PLCO trial will probably never be able to answer whether or not screening can influence 
prostate cancer mortality. In the ERSCP trial, the real benefit will only be evident after 10-
15 years of follow-up, especially because the 41% reduction of metastasis in the screening 
arm will have an impact. 
Recent sub-analysis, with longer follow up have shown a potential benefit of screening, 
lowering the number of men needed to screen, and the number of patients needed to treat to 
safe one life.  
Two key items remain open and empirical:  
 at what age should early detection start  
 what is the interval for PSA and DRE.  
A baseline PSA determination at age 40 years has been suggested upon which the 
subsequent screening interval may then be based (5) (GR: B). A screening interval of 8 years 
might be enough in men with initial PSA levels < 1 ng/mL (6) . Further PSA testing is not 
necessary in men older than 75 years and a baseline PSA < 3 ng/mL because of their very 
low risk of dying from prostate cancer (7). 
D'Amico in 1998 proposed a classification according to risk group for prostate cancer based 
on T stage, PSA value and Gleason. This has allowed to simplify the classification of patients 
with prostate cancer as well as trying to unify its treatment. (Table 1) 
The widespread use of PSA testing has led to a significant migration in stage and grade of 
prostate cancer, with > 90% of men in the current era diagnosed with clinically localised 
disease (8). Despite the trends towards lower-risk prostate cancer, 20-35% of patients with 
newly diagnosed prostate cancer are still classified as high risk, based on either PSA > 20 
ng/mL, Gleason score > 8, or an advanced clinical stage (9). Patients classified with high-
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risk prostate cancer are at an increased risk of PSA failure, the need for secondary therapy, 
metastatic progression and death from prostate cancer. Nevertheless, not all high-risk 
patients have a uniformly poor prognosis after RP (10). There is no consensus regarding the 
optimal treatment of men with high-risk prostate cancer. Decisions on whether to elect 
surgery as local therapy should be based on the best available clinical evidence. 
 
Low risk Intermediate risk High risk 
T1-T2a & PSA<10     y 
Gleason ≤6 
 T2b or PSA 10-20 or 
Glesason 7 
T2c-T3-T4 or PSA > 20 or 
Gleason ≥8 
Table 1. D'Amico classification of patients according to risk group 
As expected, survival and success of the treatment applied in prostate cancer is closely 
linked to the stadium and the risk presented by the patient. 
In this chapter we will focus on Prostate Cancer at high risk as well as the different 
therapeutic options, focusing on the radical prostatectomy as an effective treatment of the 
disease. 
2. Defining high risk prostate cancer 
The factors that best define the high risk prostate cancer are those described by D'Amico (11) 
approved by the American Urological Association in 2007 are: 
 
Gleason ≥ 8 points and / or PSA ≥ 20 and / or clinical stage ≥ T2c 
 
These high-risk tumors are at high risk for recurrence, either local or remote, so they are also 
traditionally called "locally advanced" (12) or "poorly differentiated" (13). If the patient has 
the 3 items they are considered "very high risk" and have a high probability to die from 
prostate cancer (14). 
Another factor that  has been added as a fourth factor is pretreatment PSA velocity which if 
greater 2ng/ml/year is included as criteria for high-risk disease (15,16). 
The simplification of the term "risk" has led many doctors to select patients and improperly 
included in high-risk groups. Also, following the analysis of these high-risk criteria, we can 
not quantify the individual risk to a patient, for example, with stage T2c and Gleason 8 
would have the same risk that a patient with a PSA 70 and stage T3a (17). That is why this 
classification system is inadequate and we must use another tool to individualize the risk of 
each patient; this tool are Nomograms which individually allow to analyze and quantify the 
risk presented by each patient in response to multiple risk factors or variables, integrated in 
a complex mathematical formula (18). There are plenty of nomograms (19) that have been 
designed for use in prostate cancer in recent years and could be classified into 3 groups: 
Diagnostic nomograms: those who pretend to estimate the probability of a patient developing 
prostate cancer. For example, the Vienna nomogram (20) that analyzes the number of 
cylinders to take a biopsy of the prostate. 
Staging nomograms: such as the Partin tables (21), which indicates the likelihood of organ-
confined disease. Or A. Borque neural network for predicting pathological stage in men 
undergoing radical prostatectomy. (22) 
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Prognostic nomograms: are tools that estimate the probability of success in applying a 
certain treatment to analyze different variables. The most famous and globally applied is 
Kattan nomogram (23). It analyzes a combination of three factors to determine the 
probability of PSA relapse after local therapy. These factors are: PSA, Gleason score and 
clinical stage. They apply both to radical prostatectomy, radiotherapy and brachytherapy. 
Nomograms derived from the results of treating thousands of patients. The statistical 
probability of relapse depends on the presence of pre-existing micro metastases at the 
time of local therapy (23). Hence the likelihood of relapse determined by the Kattan 
nomograms can be taken as an indication of the presence of micro metastases at the time 
of local therapy, resulting in an estimate to calculate the probability of success / failure 
when applying a certain treatment. 
In summary, nomograms are useful modern tools that exist today, which may help us 
making treatment decisions in patients with prostate cancer, especially those with high-risk 
prostate cancer. As well as providing more information to the patient. 
2.1 Locally advanced prostate cancer cT3a 
When the disease has overpassed the prostate capsule, it is a T3a stage. Typically, when a 
patient is at this stage we are advise against radical prostatectomy (24) as primary treatment 
based on the high rate of positive surgical margins and lymph node metastases (25,26). 
Numerous studies have shown that the risk/benefit of a radical prostatectomy is even more 
clear in the treatment of high risk prostate cancer (27-32), but unfortunately, there are not 
studies comparing combination therapy (radiotherapy plus hormones) with RP.  
Between 13% and 27% of patients diagnosed with stage T3 are overstimated (31,32).  
The development of CT imaging or MRI, as well as directed needle biopsies of lymph nodes 
or seminal vesicles (32), help identify patients who have less probability to benefit from a 
surgical treatment (33) as well as to plan surgery upon results. 
Due to an increased sophistication and experience of the different surgical techniques, 
there has been a decreased in operative morbidity and better functional outcomes after RP 
in stage T3 cancer than before (31,33). Urinary incontinence and erectile dysfunction 
remain the two major consequences of the surgery, but due to surgical expertise and 
experience, as well as a proper surgical planning, an improvement in functional results 
has been shown (35). 
2.2 High grade prostate cancer: Gleason score 8-10 
Patients with high Gleason score 8-10 tumors, which are confined to the prostate on 
histopathological examination, they still have a good prognosis after RP (36). The differences 
between the Gleason score biopsy and the Gleason score regarding the surgical specimen 
are between 36 and 60% of cases, although a study by Dr. Grossfeld (37) shows that 39% of 
patients had Gleason 8-10 in the biopsy specimen, showed a Gleason score of 7 or less in the 
prostatectomy speciem. 
In a recent publication (38) in which the outcome of 781 patients undergoing RP clinically 
localized stages T1-T2 was analysed, they divided into 2 groups according to Gleason: 
Gleason patients 2-7 and another group with Gleason 8-10. Over all, they showed a worse 
prognostic features and higher PSA relapse. (Table 2) 
Patients with Gleason score 8-10 prostate cancer have a higher likelihood of recurrence, but 
due to the PSA era, many of these patients are diagnosed with an early stage and therefore a 
potential local curative treatment is applicable successful (38). 
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Various studies such as those of Mian et al (39), Lau et al (40) and Soloway et al (41) analyze 
and study the survival in these patients concluded similarly. 
The clinical Gleason 8-10 is an independent prognostic factor for biochemical progression-
free survival. The radical prostatectomy remains one of the most valid treatments for these 
short of patients and providing good oncological and functional outcomes. 
 
 Group Gleason 2-7 Group Gleason  8-10 P value 
Nº of patients 673 108  
PSA (ng/ml) 
Av 13,48 
Median 9,8 
Av. 16,89 
Median 12 
0,01 
T1c 55% 50% 0,0001 
>T1c 45% 50%  
pT3b 69% 44% 0,0001 
pT3b 30% 56%  
Surgical Margin- 67% 48% 0,0001 
Surgical Margin + 33% 53%  
Biochemical 
Progression - 
74,3% 52,5% 0,0001 
Biochemical 
Progression + 
25,7% 47,5%  
Table 2. 
2.3 Prostate cancer with PSA > 20 
Different studies show that the RP in patients with a PSA> 20 is associated with a high 
recurrence rate, D'Amico and colleagues found that males with a PSA level higher than 20 
ng/ml had risk recurrence of 50% at 5 years after RP (42). Similarly, Yossepowitch 
published the results of their series of patients with PSA> 20ng/ml who underwent radical 
prostatectomy, showing a PSA recurrence rate of 44 and 53% at 4 and 20 years respectively 
(10). It is perhaps the high preoperative PSA, the factor that best relates to a worse prognosis 
preoperatively. 
On the other hand, Inman and colleagues, in their series of patients with PSA> 50ng/ml 
who underwent RP with multimodal adjuvant therapy, had biochemical progression-free 
survival at 10 years of 83% with a cancer-specific survival 87% (43). These highlights the 
potential benefit of surgery with in a multimodal approach.  
3. Therapeutic options in “high risk” prostate cancer 
3.1 Introduction 
Localized prostate cancer 
The lack of evidence regarding the effectiveness of treatment options for clinically localised 
prostate cancer continues to impact on clinical decision-making. The two such options are 
radical prostatectomy (RP) and active surveillance (AS). (44) 
For the majority of men with favorable-risk localized disease, older than 65, surveillance will 
be an attractive option that avoids adverse effects of treatment(45). But the existing trials, 
www.intechopen.com
 
Prostate Cancer – Diagnostic and Therapeutic Advances 
 
138 
provide insufficient evidence to allow confident statements to be made about the relative 
beneficial and harmful effects of RP and AS for patients with localised prostate cancer.(44) 
Klotz L et al. assure that active surveillance with treatment reserved for evidence of rapid 
PSA progression or increase in tumor volume or grade is associated with about a 3% risk of 
prostate cancer death at 10 years. (46) 
Advanced prostate cancer 
In the other hand, patients with prostate cancer continue to present with metastatic disease 
or to relapse following initial hormone therapy; for these men, the optimal combination and 
sequencing of new medical treatments must be defined. (45) 
High risk prostate cancer 
For these patients, (T2c-T3-T4 or PSA >20 or Gleason score ≥8) it is very important to give 
information about the different treatment options, and trying to adequate them to their live 
expectancy and quality of live. 
Urologist, traditionally recommended radiotherapy or androgen deprivation therapy over RP, 
not because oncologic outcomes were better with radiotherapy, but because incontinence and 
impotence rates with RP were higher, and cure rates was discouraging. (47) 
Actually, RP and radiotherapy have potential benefits and cumulative toxicities that must be 
matched to disease characteristics and patient expectations in selecting a treatment course. (48) 
3.2 Pre-treatment management in high risk prostate cancer 
A critical assessment of the location, size, and extent of the primary tumor provides 
prognostic information, is essential for treatment planning.  
D’Amico and colleagues have defined high-risk prostate cancer as that associated with any 1 
of 3 risk factors: biopsy Gleason score ≥8, PSA ≥20 ng/mL, or clinical stage ≥T2c. (11) 
More recently, D’Amico and colleagues refined their high-risk definition to incorporate an 
absolute number of high-risk features (stage ≥T2b, biopsy Gleason score ≥7, and pre-
treatment PSA >20 ng/mL). (14) Patients are classified into 1 of 3 high-risk groups, defined 
by the presence of 1, 2, or all 3 features. Probability of death from prostate cancer was 
highest among men with 3 high-risk features.  
High-risk patients with aggressive tumors (PSA >20 ng/mL and Gleason sum >7), advanced 
local lesions (T3-T4), or patients with symptoms suggestive for metastatic disease, should 
have imaging studies. (17) 
While not uniformly accurate, there are some imaging studies that help us to identificate the 
high rish disease: 
 DRE provides some evidence of the cancer’s size and pathologic stage.  
 Transrectal ultrasonography (TRUS) is extremely useful for guiding needle biopsies.  
 Computed tomography (CT) scans poorly the prostate and lack of sensitivity and 
specificity for detecting extraprostatic extension.  
 Magnetic Resonance Imaging (MRI) provides additional information about the local 
lession, it has largely replaced CT in the local staging of prostate cancer. 
 MRI has been used primarily to determine local disease extent. Body MRI has a role in 
identifying seminal vesicle involvement, but not extra capsular extension. 
 Bone Scan, which is highly sensitive but relatively nonspecific because areas of 
increased radiotracer uptake are not always secondary to osteoblastic activity from 
metastases. (17) 
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An alternative to patients risk-grouping with similar but not identical risk features is use of 
multivariable models such as nomograms. These models incorporate data from all risk 
factors relevant to the probability of treatment failure and proportionately weigh their 
relative contribution in order to calculate a risk score. (48) 
Eastham et al. demonstrate that high-risk patients were more likely to exhibit adverse 
pathologic features and to have biochemical progression. Nevertheless, roughly one-third of 
high-risk patients (22% to 63%, depending on the definition) had organ-confined cancers 
and roughly half (41% to 74%) remained progression-free 10 years after surgery alone. These 
results confirm that current definitions of high risk disease are unreliable in identifying 
patients who cannot be cured by local therapy. (48) 
3.3 Objectives of treatment in high risk prostate cancer 
The actual objectives of the treatment of high prostate cancer are: 
1. To offer a radical treatment 
2. Trying to decrease prostate cancer progression  
3. To increase metastatic disease free interval  
4. To provide a proper quality of life. 
Men with high-volume lesions or high-stage yet clinically localized disease must receive 
multimodal therapy. More advances will require concerted efforts through clinical trials. (45) 
Neoadjuvant Androgen Deprivation Therapy may indeed provide no additional benefit 
over surgery alone for patients with clinically localized prostate cancer. Recent studies have 
demonstrated the feasibility of neoadjuvant chemotherapy prior to RP in patients with high-
risk prostate cancer. (17). If such a strategy was shown to be effective, future clinical practice 
could be altered significantly. A randomized phase 3 clinical trial, CALGB 90203, is 
currently investigating whether neoadjuvant chemo-hormonal therapy followed by RP 
reduces the risk of biochemical recurrence when compared to RP alone. 
3.4 Actual treatment in high risk prostate cancer 
Actually, the optimal treatment are: 
- radical prostatectomy (RP) + radiation therapy (RT) 
- radical prostatectomy  + hormonotherapy 
- radiation therapy + hormone therapy 
There is no consensus regarding the optimal treatment of men with high-risk PCa.  
Surgery is showing good results, but decisions on whether to elect surgery as local therapy 
should be based on the best available clinical evidence. (49) 
On the other hand, it has been recently assessed the effect of RP and RT on the rate of 
distant metastases in patients with clinically localized prostate cancer on the study from 
Memorial Sloan Kettering Cancer Center comparing patients whom underwent surgery 
versus radiotherapy (50). Patients with clinical stages T1c-T3b prostate cancer treated with 
intensity-modulated RT (81 Gy) from 1998 to 2002 were compared with similar cohort of 
men treated with RP.  
This study, showed that patients with higher-risk disease, treated with RP had a lower risk 
of metastatic progression and prostate cancer-specific death, than men treated with RT. The 
metastatic progression is infrequent in men with low-risk prostate cancer, treated with 
either RP or RT.  
These results, despite being from retrospective review of patients treated at a single 
institution, certainly suggest that RP should be considered as a treatment option in men 
with clinically localized, high-risk prostate cancer. (50) 
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As mentioned above, the multimodal treatment is achieving good results, and to corroborate 
this, several randomised studies of radiotherapy combined with androgen-deprivation 
therapy (ADT) versus radiotherapy alone have shown a clear advantage for combination 
treatment, but no trial has ever proven combined treatment to be superior to RP. 
4. Radical prostatectomy in high risk CaP 
4.1 Introduction 
Actually radical prostatectomy is accepted as an election treatment in both low and high 
risk prostate cancer with different evidence level, and even for very high risk prostate 
cancer. (Table 3) 
 
INDICATIONS LE 
In patients with low and intermediate risk localised PCa (cT1a-T2b and 
Gleason score 2-7 and PSA ≤ 20) and a life expectancy > 10 years 1b 
Optional  
Patients with stage T1a disease and a life expectancy >15 yr or Gleason score 7 3 
Selected patients with low-volume high-risk localised PCa (cT3a or Gleason 
score 8-10 or PSA > 20) 
3 
Highly selected patients with very high-risk localised PCa (cT3b-T4 N0 or any 
T N1) in the context of multimodality treatment 
3 
Optional for selected patients with T3a, PSA < 20 ng/mL, biopsy Gleason 
score ≤ 8 and a life expectancy > 10 years. 3 
Table 3. 
The goals of RP are to remove the cancer completely with negative surgical margins, minimal 
blood loss, no serious perioperative complications, and complete recovery of potency and 
urinary continence. From an oncologic standpoint, obtaining negative surgical margins is 
paramount. A positive surgical margin has been associated with as much as 4-fold higher risk 
of biochemical recurrence, even after adjusting for other prognostic factors such as Gleason 
grade, extracapsular extension, seminal vesicle invasion, and lymph node metastasis. (48) 
On the same way, there are good results in terms of morbidity and survival when radical 
prostatectomy is offered as a radical treatment. 
4.2 Evidence of RP in HR.PC 
RP in locally advanced PCa: cT3a 
Is defined, as cancer that has perforated the prostate capsule. Surgical treatment has 
traditionally been discouraged, mainly because patients have an increased risk of positive 
surgical margins and lymph node metastases and/or distant relapse  
In recent years, there has been renewed interest in surgery for locally advanced PCa, and 
several retrospective case-series have been published. In general, 33.5-66% of patients will 
have positive section margins, and 7.9-49% will have positive lymph nodes. 
On the other hand, excellent 5-, 10- and 15-year overall survival (OS) and cancer-specific 
survival (CSS) rates have been published.  
Therefore, it is increasingly evident that surgery has a place in treating locally advanced 
disease (45) 
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The problem remains on patient selection before surgery: Nomograms, nodal imaging with 
CT and seminal vesicle imaging with magnetic resonance or directed specific puncture 
biopsies of the nodes or seminal vesicles can help to identify those patients unlikely to 
benefit from a surgical approach. (17) 
In addition, it is extremely important that radical prostatectomy for clinical T3 cancer 
requires sufficient surgical expertise to keep an acceptable morbidity level.  
RP in High-grade PCa: Gleason score 8-10 
In this group of patients, the incidence of organ-confined disease is around 26% to 31%. The 
PSA value and percentage of positive prostate biopsies may help to select men with high-
grade PCa most likely to benefit from RP.  
Rioja Zuazu J. et al. (38) analyzed the characteristics of the clinical Gleason 8-10 group of 
patients within their series of patients diagnosed with prostate cancer and treated by means 
of radical prostatectomy, and tried to ascertain which were the influence factors within this 
group, upon progression and progression free survival. They conclude, that Clinical 
Gleason Score 8-10 is a negative independent prognostic factor on the progression free 
survival, but its prognosis is better if they present a PSA prior surgery lower than 11 ng/ml 
and the pathological stage is a pT2. So, these kind of patients could be beneficed of RP. 
RP in PCa with PSA > 20 
Yossepowitch et al. (19) and D’Amico et al. (15) have investigated the results of RP in these 
patients.   In all cases, very good results were seen, with a cancer- specific survival of up to 
91% in 10 years in patients treated with RP. 
More recently, Inman and co-workers (43) described the long-term outcomes of RP with 
multimodal adjuvant therapy in men with PSA > 50. Systemic progression-free survival 
rates at 10 years were 83% and 74% for PSA 50-99 and > 100, respectively, while CSS was 
87% for the whole group. These results argue for aggressive management with RP as the 
initial step. 
RP in cT3b-T4 N0 
Provided that the tumour is not fixed to the pelvic wall, or that there is no invasion of the 
urethral sphincter, RP is a reasonable first step in selected patients with a low tumour volume.  
In 2005, The Mayo Clinic reported a series of patients with seminal invasion, treated with RP 
+ HT adjuvant. They had a progression free survival at 5, 10 and 15 years, of 85%, 73% and 
67% respectively, and a cancer specific survival of  95%, 90% and 79%.  
Despite this, management decisions should be made after all treatments, and should be 
discussed by a multidisciplinary team, and after balancing benefits and side-effects of each 
therapy modality by the patient, with regard to his own individual circumstances, decision 
has to be taken.  
4.3 Optimal surgical technique for high risk cancer 
Surgeons must understand the important anatomical and surgical principles that will allow 
them to improve their own technique, particularly when operating in the high-risk setting. 
Certain principles are important, and apply equally to open, laparoscopic and robotic 
surgical techniques.  
Even in a patient with a high risk of extra prostatic disease, a portion of the neurovascular 
bundle can often be preserved. (17) 
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This approach has been facilitated by recent anatomical descriptions of the periprostatic 
anatomy. (51) 
Dissection of the neurovascular bundles can be done in an intrafascial plane (directly 
adjacent to the prostatic capsule; complete nerve sparing), an interfascial plane (within the 
lateral prostatic fascia; partial nerve sparing) and extrafascial plane (outside the lateral 
prostatic fascia; nerve resection) 
Deep dissection beneath Denonvilliers’ fascia posteriorly should be performed routinely, as 
few nerves are present in this area and deep dissection will reduce the incidence of 
posterolateral margins. 
Large, high-grade cancers, near the base of the prostate, or in the anterior transition zone 
often invade the bladder neck. For anterior cancers, begin division of the bladder neck a 
centimeter or more from its junction with the prostate. For large posterior tumors or those 
with seminal vesicle invasion, include the posterior bladder distal to the interureteral ridge 
in the specimen. (48) 
5. Pelvic lymph node dissection 
For patients with low risk disease, PLND is not necessary and is not recommended, because 
the chance of metastasis is low. 
For patients with high and intermediate risk disease, extended PLND at least for external 
iliac, obturator and hypogastric lymph nodes should be performed during radical 
prostatectomy. Removing at least 10 lymph nodes is recommended to detect LNI. (52) 
Prostate cancer lymphatic spread ascends from the pelvis up to the retroperitoneum 
invariably through common iliac lymph nodes. PC lymphatic spread can be divided in two 
main levels: pelvic and common iliac plus retroperitoneal lymph nodes. (53) 
So the technique try to remove all lymphatic tissue between the external iliac vein and 
hypogastric vein above and below the obturator nerve, including the hypogastric and 
obturator lymph nodes. 
Therefore may assert that an eLND should be performed in all high-risk cases, as the 
estimated risk for positive lymph nodes will be in the range 15-40%. (10) 
However, despite the above, some authors like Bubley are not so categorical in affirming this. 
Although it is generally accepted that eLND provides important information for prognosis 
(number of nodes  involved, tumour volume within the lymph node, capsular perforation of 
the node) that cannot be matched  by any other current procedure, consensus has not been 
reached as to when eLND is indicated and to what extent it should be performed. When 
making such decisions, many physicians rely on nomograms based on  pre-operative 
biochemical markers and biopsies. (54) 
5.1 Role of RT in high risk prostate cancer 
Indications for RT after RP 
As stated earlier, currently, a multimodal treatment is chosen to increase survival and 
reduce biochemical progression. In this sense the RT play an important role. 
There are two important studies about this: 
The EORTC Trial 22911 included 1,005 patients with positive surgical margins or pT3 
disease (extracapsular extension and seminal vesicle involvement) and randomized them 
to adjuvant EBRT (50 Gy to the prostatic fossa and periprostatic tissue plus a 10–14 Gy 
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boost to the prostatic fossa only) versus no immediate treatment. (55) The cumulative rate 
of loco regional failure was significantly lower in the irradiated group (P <0.0001). 
However, other clinically important endpoints were not improved. In particular, 5-year 
metastasis-free survival, cause-specific survival, and overall survival were not affected by 
adjuvant RT. 
The Southwest Oncology Group (SWOG) trial 8794 included 425 patients with high-risk 
localized disease, who were randomized to receive either 60–64 Gy to the prostatic fossa or 
observation only. (56) Biochemical control, disease-free survival, cancer-specific mortality, 
and overall survival were significantly increased in the adjuvant irradiation arm at a median 
follow-up of 10.6 years. 
Both the EORTC and SWOG randomized trials, provide evidence that adjuvant post-
prostatectomy irradiation reduces the risk of biochemical recurrence and local clinical 
failure. It remains uncertain, whether administration of radiation immediately after PSA is 
detected, could provide equally effective long-term outcomes to patients receiving 
adjuvant therapy, while sparing such patients from unnecessary irradiation. (17) (48) 
Salvage radiotherapy 
The efficacy of radiotherapy in the setting of a rising PSA after RP is unproven, and its use is 
highly controversial. Stephenson et al. reported on a large retrospective analysis of salvage 
irradiation of 501 patients from 5 institutions. (57) 
Positive surgical margins, Gleason scores <8, or PSADT >10 months. In such patients, PSA 
relapse-free survival outcomes were in the range of 70% to 80% at 3 years. 
6. Survival 
Regarding cancer-specific survival rate, and the overall survival rate, there are many 
studies, with different results (table 4). 
First, in terms of morbidity, Berglund and colleagues (58) showed, that recovery from 
surgery, duration of catheterization, and the overall return of continence were essentially 
similar to those observed in the low-risk population.  
Another important factor to consider when analyzing survival, is the overstaging sometimes 
happens in the T3. Therefore, Ward et al report a long-term experience with radical surgery 
in patients presenting with locally advanced (cT3) prostate cancer, as the best management 
of such patients remains a problem. They found that, significantly many patients with cT3 
prostate cancer were over-staged (pT2) in the PSA era, and RP as part of a multimodal 
treatment strategy for patients with cT3 disease offers cancer control and survival rates 
approaching those achieved for cT2 disease. (31) 
For short term survival, Loeb et al (35) reported a complication rate of 11% in 288 
consecutive high-risk patients treated by RP, which was not different from the rate in a 
previous study from the same group that included 3,477 consecutive patients with prostate 
cancer (59) when analyzing intermediate-term cancer control, and quality-of-life outcomes 
after radical retropubic prostatectomy (RRP), and concluded that RRP offers excellent 
intermediate-term cancer control for selected men, of all ages, who present with high-risk or 
locally advanced disease. Both, continence and potency, were preserved in most patients, 
although the potency rates were significantly greater for the younger men. RRP with 
appropiate postoperative radiotherapy and/or hormonal therapy is a reasonable treatment 
option for selected men with high-risk or locally advanced disease. (35) (Table 4) 
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 ↑Risk Nº 
Patients 
% 5 years BR 
free survival
% 10 years cancer especif 
survival 
Van de 
Ouden (29) 
T3 clínic 136 39 72 
Hsu (26) T3 clínic 235 60 92 
Ward (20) T3 clínic 841 58 90; 15 y 79 
Lau (23) Gleason 8-10 407 49 85 
Berglund (19) 
PSA ≥15 or Gleason 
8-10 
281 65 NR 
Loeb (21) 
T2 and Gleason 8-10 
or PSA ≥15 o T3 288 39-53 70-93 
Van Poppel 
(27) 
T3a y PSA ≤20 and  
Gleason ≤7 32 3mo:90 NR 
BR: Bioquimical recurrence 
NR: No results. 
Table 4. 
For long term survival, Van Poppel (60) showed in 2006, that in patients with locally 
advanced disease, the cancer-specific survival rate after RP at 5- and 10-years of follow-up, 
was 85-100% and 57-91.6%, respectively. The overall survival rate at 5 and 10 yr was, 75% 
and 60%, respectively. In patients with high-grade prostate cancer (Gleason score> or =8), 
the biochemical recurrence-free survival, after RP at 5 and 10 yr of follow-up was, 51% and 
39%, respectively. 
Van Der Ouden et al. determined the progression and survival rates, and investigate 
subgroups of patients who may not benefit from this treatment. Defining that Radical 
prostatectomy as monotherapy, in patients with locally advanced non-metastatic prostate 
cancer (T3) produces acceptable results, in those with well or moderately differentiated 
tumors. The results of progression and survival, are not significantly different from those  
patients with organ confined prostate cancer. (29) 
Yossepowitch describe the results of RP in their patient’s serie, classify patients in risk groups: 
(61) he studied pathological and clinical outcomes among high-risk patients treated with RP. 
To identify high-risk subsets, eight definitions from the medical literature were applied. 
Depending on the criteria, high-risk patients comprised 3% to 38% of the entire study 
population, highlighting the immense variability among available high-risk definitions.  
High-risk patients were more likely to exhibit adverse pathological features (35%–71% with 
extra capsular extension, 10%–33% with seminal vesicle invasion, and 7%–23% with lymph 
node involvement), but roughly one third (22%–63%) had organ-confined cancers and 
nearly half (41%–74%) remained progression-free 10 years after surgery alone. (Table 5) 
More recently the group from the Mayo Clinic, has reported their long-term result after 
radical prostatectomy versus external bean radiotherapy for patients with high-risk prostate 
cancer. (62) The 10-year cancer specific survival rate was 92%, 92% and 88% after RRP, EBRT 
plus ADT and EBRT alone. After adjusting for case mix, no significant differences in the 
risks of systemic progression or prostate cancer death were observed between patients who 
received EBRT plus ADT and patients who underwent RRP. However, the risk of all causes 
of mortality was greater, and statistically significant, after EBRT plus ADT than after RRP.  
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Criterion R Nº patients % confined 
organ 
% free survival in 
5 years 
% cancer specific 
survival in 10 
years 
Gleason 8-10 274 35 53 88 
PSA > 20 275 33 56 91 
T3c(*year 1992) 144 22 49 89 
Nomogram PFP 
5 years ≤50% 391 28 53 92 
PSA velocity >2 
ng/mL/year 
952 63 80 97 
PSA≥ 20 o ≥T2c o 
Gleason 8-10 
957 43 68 93 
PSA≥15 o T2Bc o 
Gleason 8-10 
1752 51 73 95 
Table 5. 
7. Local control  
Local control, main objective with both techniques, is better achieved with surgery. Local 
relapse rates between 3-30%(63-65) Depends on clinical stage (pT2: 2-7%; negative margins 
7%; pT3-4: 40%; positive margin 27%) While with Radiotherapy, local recurrence rate is for 
T1: 17-22% (Standford); 4.6% (Schelhamer); T2: 19%-35%.  
The rate of positive biopsies is between 20-70%, although is difficult to classify its meaning, 
they highlight disease and progression. It depend on clinical stage (B=17%, C=59%) and 
Gleason score. A valuable biopsy is at 18 months after finishing treatment.  
Frequency of positive prostate biopsies on patients whom underwent radiotherapy, is 
around 38% on average.  
In the study (66) with 100 patients, with biopsy every 6 months showed following results T-
1b: 21%; en T-2a: 24%; en T-2b-c: 28%.  
There is no doubt regarding its prognostic value. Although the pioneers showing these results 
were Rhamy (1972) and Sewel (1975) Scardino has been reporting, and highlighting its value 
(67). At Baylor-Collegue (Houston) 147 patients treated with Au 198 and external bean 
radiotherapy, clinical stage A2, B, C with pelvic lymphadenectomy. They had a positive 
biopsy rate of 42%, 36%, 28% at 6, 12 and 18 months. The chance of local recurrence at 5 years 
for positive and negative biopsies is around 52% and 12%, and at 10 years of 72% and 30%.  
8. Conclusions 
Many cancers, categorized clinically as high risk, are actually pathologically confined to the 
prostate, and most men with such cancers who undergo RP, are free of additional therapy 
long after surgery. 
For men with high-risk, clinically localized prostate cancer, decisions on whether to elect 
surgery as local definitive therapy should be based on the best available clinical evidence 
rather than on an individual practitioner’s experiences and biases. 
www.intechopen.com
 
Prostate Cancer – Diagnostic and Therapeutic Advances 
 
146 
Patients classified with high-risk prostate cancer, by commonly used definitions, are at 
increased risk of PSA failure, need for secondary therapy, metastatic progression, and death 
from systemic disease. Nevertheless, such high risk patients do not have a uniformly poor 
prognosis after RP. 
- If the prostate cancer risk has a high probability of progression to metastasis or death, 
we must offer aggressive treatment, which achieves high cure rate, and eliminate the 
illness onset. 
- Radical prostatectomy is proving a very valid option with high success rate, for which 
we must select patients appropriately 
- The success of RP in high-risk patients, with stage T3 resection depends entirely local 
tissue containing the tumor and include the resection of seminal vesicles and extended 
lymphadenectomy. 
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